Similarly, Sylvia et al. [43] conducted the phase II clinical study (NCT03971461) to use 177Lu-DOTATATE, a radiopharmaceutical targeting SSTR2, for treating patients with progressive meningiomas who had not responded to surgery or radiotherapy. This evidence concerns the gene SSTR2 and meningioma.